Paprotrain
CAS: 57046-73-8
Ref. 3D-HCA04673
5mg | Descatalogado | ||
10mg | Descatalogado | ||
25mg | Descatalogado | ||
50mg | Descatalogado | ||
100mg | Descatalogado |
Información del producto
Paprotrain is a potent inhibitor of epidermal growth factor receptor (EGFR) that binds to the EGFR and inhibits its activity. It has been shown to inhibit the growth of cancer cells resistant to other EGFR inhibitors, such as gefitinib and erlotinib. Paprotrain also inhibits tumour cell viability in vitro by inducing apoptosis. In addition, it has been shown to inhibit the phosphorylation of kinesin and actin filaments, which are involved in cell motility and proliferation. This drug has prognostic value in prostate and breast cancer because it is associated with a poor prognosis.